| Drug Name |
Tamsulosin |
| Drug ID |
BADD_D02113 |
| Description |
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.[A178351]
Tamsulosin was first approved by the FDA on April 15, 1997.[L6238] |
| Indications and Usage |
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.[Label]
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.[A178339,L6259] |
| Marketing Status |
approved; investigational |
| ATC Code |
G04CA02 |
| DrugBank ID |
DB00706
|
| KEGG ID |
D08560
|
| MeSH ID |
D000077409
|
| PubChem ID |
60147
|
| TTD Drug ID |
D05MBZ
|
| NDC Product Code |
Not Available |
| UNII |
G3P28OML5I
|
| Synonyms |
Tamsulosin | LY 253352 | LY-253352 | Tamsulosin Hydrochloride | 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | Flomax | YM 617 | YM-617 |
